More News

Ophthalmic Company Revenue Drops 4.5 Percent in Third Quarter of 2025

Ophthalmic manufacturer revenue in Q3-2025 totaled $11.5 billion. Revenue decreased 4.5 percent from the same quarter in 2024 and decreased 1.8 percent from Q2-2025. The total includes Market Scope...

New Products Power Revenue Growth in Dry Eye Pharmaceuticals

Three new drugs shaking up the dry eye pharma market in the US are poised to drive revenue growth in the next five years. Xdemvy (lotilaner ophthalmic solution), from Tarsus Pharmaceuticals, has be...

Dry Eye Device Field Gets More Crowded With Product Launches

The dry eye procedure market is relatively small, but barriers to entry are low, and that is attractive for new competitors. Asian companies, from China and South Korea, launched new machines in th...

Birth Tissue Grafts are Experiencing Immense Momentum as Cornea Treatment

Birth tissue grafts are a major growth area in the cornea products market, with expanding indications and many manufacturers. Demand for birth tissue has skyrocketed throughout the past decade and ...

Cellution Launches AmnioPlast Allografts in US for Ocular Surface Repair

Cellution Biologics announced Nov. 19 the US launch of its AmnioPlast 1 monolayer and AmnioPlast Double dual-layer dehydrated amnion membrane allografts for ocular surface repair. The Roswell, Geor...

Precise Bio Implants World’s First 3D Bioprinted Cornea in Patient in Israel

Precise Bio announced Nov. 19 that the first patient had been treated with PB-001, the company’s 3D bioprinted corneal implant candidate, in a Phase I clinical trial. The legally blind patient was ...

Iolyx Licenses Autoimmune Dry Eye Candidate to Théa in Deal Worth Up to $280 Million

Iolyx Therapeutics announced Dec. 3 that it had granted rights worldwide, excluding Asia, to France’s Laboratoires Théa to develop and commercialize ILYX-002, an immune-modulating eye drop candidat...

Select US FDA Approvals and Clearances in November 2025

The US FDA’s ophthalmic device division granted clearance to two devices using the 510(k) pathway in November 2025, according to the agency’s database. Topcon received clearance for its TRK-3 Omnia...

PDUFA Dates for Ophthalmic Drug Candidates, December 2025

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

Alcon Raises Bid for STAAR; Large Shareholders Continue to Oppose Deal

Alcon reported Dec. 9 that it had amended its bid for phakic IOL maker STAAR Surgical, raising its offer to $30.75 per share in cash, up from $28 in August. The 9.8 increase did little to appease s...

Bascom Palmer Eye Institute Opens Location in Abu Dhabi

The Bascom Palmer Eye Institute, part of the University of Miami Health System, announced that it had opened its first international location in Abu Dhabi, United Arab Emirates, in November. The pr...

Duke Becomes First Academic Center to Implant Encelto

Duke Eye Center, of Durham, North Carolina, reported Oct. 28 that it had become the first US academic medical center to implant Encelto. Encelto, an encapsulated cell-based gene therapy implant, is...

Belite Leads Latest Ophthalmic Fundraising with $350 Million Offering

Belite Bio led recent ophthalmic fundraising efforts with a $350 million offering to prepare for commercial-ization of oral tinlarebant for geographic atrophy and Stargardt. Financing announced in ...

US FDA Approves Eylea HD for RVO, Plus Monthly Dosing in All Approved Indications

Regeneron Pharmaceuticals announced Nov. 19 that the US FDA had approved Eylea HD (aflibercept 8 mg) for macular edema following retinal vein occlusion (RVO), with dosing up to every eight weeks af...

MIT Research Offers New Treatment Approach for Amblyopia

MIT researchers have demonstrated a new strategy for treating amblyopia in adults. The team showed that if the retina of the amblyopic eye is temporarily and reversibly anesthetized for a couple of...

Two Leading Eye Banks Based in Southeastern US Announce Merger

Two US eye banks, Advancing Sight Network and Miracles In Sight, announced Nov. 6 that they would merge and begin operating as one on Jan. 1, 2026. Advancing Sight Network, of Birmingham, Alabama, ...

US FDA Gives Green Light to Trial of EyeYon’s EndoArt Artificial Corneal Implant

Israel’s EyeYon Medical announced Dec. 8 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a trial of EndoArt, a syntheti...

Bausch + Lomb Outlines Growth Plans, Driven by Deep Pipeline

Bausch + Lomb used its investor day on Nov. 13 to lay out how it plans to produce growth of 6 to 8 percent in its surgical segment and 5 to 7 percent in its pharmaceutical, consumer, and contact le...

Finland Researchers Study Heat’s Role in Slowing Progression of Dry AMD

Researchers at Aalto University in Finland announced Oct. 29 a promising approach to stopping the progression of dry age-related macular degeneration by using heat to trigger healing responses at t...

CDER Chief Pazdur Retiring from US FDA; Makary Names Høeg as Replacement

Oncologist Richard Pazdur, MD, is reportedly retiring from his role as the US FDA’s director of the Center for Drug Evaluation and Research (CDER) after less than a month in the job. The FDA announ...

Emerging Companies Pursuing Ophthalmic Indications, December 2025

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Weekly Poll of US MDs and ODs, December 2025

Clinical Trial Updates for Ophthalmic Candidates, December 2025

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

December 2025 Ophthalmic News Briefs

Topcon Healthcare announced on Nov. 18 the FDA 510(k) clearance and US commercial launch of the TRK-3 Omnia, an automated four-in-one diagnostic device that integrates objective refraction, keratom...

AAO Retina Sessions Delve into Wide-field Imaging, Diabetic Eye Disease, and More

Approximately 2,300 doctors attended the Retina Subspecialty Day at the 2025 AAO meeting, and many stayed to take part in retina sessions during the remaining days of the conference. Highlights of ...